Singapore markets close in 5 hours 53 minutes

Straits Times Index
3,312.03
+4.13(+0.12%)
Nikkei
38,913.48
+296.38(+0.77%)
Hang Seng
18,921.02
-274.58(-1.43%)
FTSE 100
8,370.33
-46.12(-0.55%)
Bitcoin USD
69,432.10
-552.61(-0.79%)
CMC Crypto 200
1,511.53
-14.89(-0.98%)

Neumora Therapeutics, Inc. (NMRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

9.65

+0.20

(+2.12%)

At close: 04:00PM EDT

9.88

+0.23

(+2.38%)

After hours:

07:59PM EDT

Trade prices are not sourced from all markets

All

Simply Wall St.
This Neumora Therapeutics Insider Increased Their Holding In The Last Year
Insiders were net buyers of Neumora Therapeutics, Inc.'s ( NASDAQ:NMRA ) stock during the past year. That is, insiders...
GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also currently in Phase 3 development for the treatment of MDD with data from KOASTAL-1 anticipated in the fourth quarter of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pip
GlobeNewswire
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer's disease agitation with NMRA-511 Strong financial position with $423.0 million in cash, cash equivalents and marketable securities expected to support operations into 2026, providing runway through multi